These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 25733103)
1. The HIV-1 transgenic rat model of neuroHIV. Vigorito M; Connaghan KP; Chang SL Brain Behav Immun; 2015 Aug; 48():336-49. PubMed ID: 25733103 [TBL] [Abstract][Full Text] [Related]
2. Modulatory Effects of Nicotine on neuroHIV/neuroAIDS. Han H; Yang Z; Chang SL; Li MD J Neuroimmune Pharmacol; 2018 Dec; 13(4):467-478. PubMed ID: 30215204 [TBL] [Abstract][Full Text] [Related]
3. Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. Lashomb AL; Vigorito M; Chang SL J Neurovirol; 2009 Jan; 15(1):14-24. PubMed ID: 19085205 [TBL] [Abstract][Full Text] [Related]
4. HIV Neuropathogenesis in the Presence of a Disrupted Dopamine System. Nickoloff-Bybel EA; Calderon TM; Gaskill PJ; Berman JW J Neuroimmune Pharmacol; 2020 Dec; 15(4):729-742. PubMed ID: 32506353 [TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 2017 ISEV symposium on "HIV, NeuroHIV, drug abuse, & EVs". Hu G; Yelamanchili S; Kashanchi F; Haughey N; Bond VC; Witwer KW; Pulliam L; Buch S J Neurovirol; 2017 Dec; 23(6):935-940. PubMed ID: 29147885 [TBL] [Abstract][Full Text] [Related]
6. The far-reaching HAND of cART: cART effects on astrocytes. Gonzalez H; Podany A; Al-Harthi L; Wallace J J Neuroimmune Pharmacol; 2021 Mar; 16(1):144-158. PubMed ID: 32147775 [TBL] [Abstract][Full Text] [Related]
7. Disruption of Timing: NeuroHIV Progression in the Post-cART Era. McLaurin KA; Li H; Booze RM; Mactutus CF Sci Rep; 2019 Jan; 9(1):827. PubMed ID: 30696863 [TBL] [Abstract][Full Text] [Related]
8. HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum. Zhu J; Yuan Y; Midde NM; Gomez AM; Sun WL; Quizon PM; Zhan CG J Neurovirol; 2016 Jun; 22(3):282-92. PubMed ID: 26501780 [TBL] [Abstract][Full Text] [Related]
9. Evolution of the HIV-1 transgenic rat: utility in assessing the progression of HIV-1-associated neurocognitive disorders. McLaurin KA; Booze RM; Mactutus CF J Neurovirol; 2018 Apr; 24(2):229-245. PubMed ID: 28730408 [TBL] [Abstract][Full Text] [Related]
11. Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Sacktor N; Robertson K Curr Opin HIV AIDS; 2014 Nov; 9(6):517-20. PubMed ID: 25203640 [TBL] [Abstract][Full Text] [Related]
12. Neuropsychological Assessment of 412 HIV-Infected Individuals in São Paulo, Brazil. Gascón MRP; Vidal JE; Mazzaro YM; Smid J; Marcusso RMN; Capitão CG; Coutinho EM; Benute GRG; De Lucia MCS; de Oliveira ACP AIDS Patient Care STDS; 2018 Jan; 32(1):1-8. PubMed ID: 29323557 [TBL] [Abstract][Full Text] [Related]
13. Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV. Matt SM; Nickoloff-Bybel EA; Rong Y; Runner K; Johnson H; O'Connor MH; Haddad EK; Gaskill PJ Front Immunol; 2021; 12():663061. PubMed ID: 34093554 [TBL] [Abstract][Full Text] [Related]
14. Effects of docosahexaenoic acid on locomotor activity in ethanol-treated HIV-1 transgenic rats. He J; Huang W; Zheng S; Vigorito M; Chang SL J Neurovirol; 2018 Feb; 24(1):88-97. PubMed ID: 29260441 [TBL] [Abstract][Full Text] [Related]
15. Acquisition and long-term retention of spatial learning in the human immunodeficiency virus-1 transgenic rat: effects of repeated nicotine treatment. Vigorito M; Cao J; Li MD; Chang SL J Neurovirol; 2013 Apr; 19(2):157-65. PubMed ID: 23456952 [TBL] [Abstract][Full Text] [Related]
16. Opioid and neuroHIV Comorbidity - Current and Future Perspectives. Fitting S; McRae M; Hauser KF J Neuroimmune Pharmacol; 2020 Dec; 15(4):584-627. PubMed ID: 32876803 [TBL] [Abstract][Full Text] [Related]